Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS Communications Could Get Refreshed After Advisory Panel Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Risk Communications Advisory Committee will address methods for presenting REMS information and assessing whether it is reaching the target population.

Advertisement

Related Content

REMS Modification Guidance Coming As FDA Rejects Petition For Shared REMS Rules
REMS Modification Studies Could Use Foreign Markets As Controls
How To Speak REMS: Structured Product Labeling Seen As Route To Standardization
Whose Burden Is It Anyway? REMS’ Health Care Impact Belongs To FDA, PhRMA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS075218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel